trial · primary record
LPX-TI641
Rheumatoid Arthritis (RA)
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 48 |
| Primary completion | 2027-02-15 |
| Primary endpoint | To evaluate the safety and tolerability after multiple oral doses of LPX-TI641 in participants with RA and PsA. |
| Registry ID | NCT06628206 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:16.668Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06628206
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.